Intelligent Ultrasound Share Discussion Threads

[bamboo2] 11/9/2023 07:04

11/09/2023 7:00am
RNS Non-Regulatory

TIDMIUG

Intelligent Ultrasound Group PLC

11 September 2023

SonoLystlive, powered by Intelligent Ultrasound's ScanNav AI, launches on new GE Healthcare Voluson Expert Series ultrasound machines

Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces that GE Healthcare has launched SonoLystlive onto its latest version of the Voluson Expert Series portfolio of ultrasound machines.

Powered by Intelligent Ultrasound's ScanNav AI software, SonoLystlive takes ultrasound image recognition to the next level by automatically capturing images in real-time, as the clinician scans a mid-trimester patient. Using practice guidelines from the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the AI software automatically recognises the anatomy, captures the image and checks it off the list of required views. By minimising the need to manually freeze, annotate and store images, the software significantly reduces keystrokes and exam time for sonographers.

This new technology further builds on Intelligent Ultrasound's long-term partnership agreement with GE HealthCare, which already incorporated Intelligent Ultrasound's AI technology as an option add-on in its SonoLyst X/IR software on the Voluson Expert 22 and SWIFT ultrasound machines.

SonoLystlive was demonstrated live at the International Symposium on Fetal Anomalies in London, on the 9 and 10 September by Prof Aris Papageorghiou. The full launch will take place at the ISUOG World Congress in Seoul, South Korea from the 16-19 October.

Stuart Gall, CEO of Intelligent Ultrasound, commented:

"We are delighted that, by incorporating SonoLystlive onto its Voluson Expert Series ultrasound machines [1] , GE Healthcare is leading the way in using AI software to improve obstetric workflows for the benefit of clinicians and patients. The Voluson Expert Series is a market-leading ultrasound machine in the global women's healthcare obstetrics market and SonoLystlive is a fantastic example of how AI software can help save scanning time, whilst de-stressing the scanning environment for the sonographer.

We look forward to continuing our partnership with GE HealthCare and we remain excited that our novel 'classroom-to-clinic' approach is making clinical diagnostic ultrasound easier to learn and simpler to use."

This announcement contains inside information for the purposes of the UK version of Article 7 of Regulation (EU) 596/2014.

[40 fathoms] 08/9/2023 12:50

Bamboo, you make a good point. IP Group with its veto power, if and when a deal comes (is accepted) will make sure it is a fair one, or at least a fair from an institutional perspective.

IP Group is insanely cheap at these levels. It is trading at an almost 60% discount to a portfolio that has +250 million in cash and portfolio companies with valuations on the floor. Also plenty of bargains out there where the cash can be put to good use.

The reason, beyond valuation, why I think AIM is so attractive at the moment is because it is the Instos that have bailed out and one thing is certain they will return and for the quality names when the whistle blows they will want to be in yesterday, and not the way they exited by dribbling out shares over many months or in some cases now years. For the quality names and the Instos the doors will be very, very narrow for them on the way back in.

IUG has been a bit of an exception, its top 10 shareholders have been very solid and have all put their hand in the pocket when they have been asked.

[bamboo2] 08/9/2023 01:13

hi, 40F, I bought into DNL last Summer 2022 for the t/o potential and a t/o was announced 30/8/2022.

Co-incidentally, it shared the IPGroup stable with IUG, and as we know, in recent years IPGroup always seem ready to do a deal. Like IUG, DNL was too, on the cusp of becoming profitable.

The DNL share price had been 11.25, the offer was 27.5p [premium approx 150%].

I reckon if we worked on that kind of basis, we'd be in the right ball park.

IUG 11 x 150% = 27.5p

Further info...

[40 fathoms] 07/9/2023 23:15

I think it all depends as we are prisoners to our share price. In the end any offer will be a function of share price at the time and not necessary a reflection of true value.

Assuming the companies evolution of revenue and profit comes to pass, I think an offer today would come at about 20p, this would be 30p this time next year. I think in 2025 or 2026 it starts to get interesting as you would then expect the share price to reflect the fact that we would be significantly profitable, with a clear path to GBP 10 million of annual profit and plenty of growth still to come from product development and products under development. I think then an offer would come at well north of 60p.

[bamboo2] 07/9/2023 18:04

40F, any idea on price?

They must be aware that Gall is over 60, and will presumably want to achieve other things in life.

[40 fathoms] 07/9/2023 14:51

I think one thing is now clear, at some point GEHC will offer Sonolyst as standard on all its machines. It appears this will trigger annual royalty payment of about $ 5 million per year, add the second product that we are developing for them and then the Gestational Age product we have recently patented and GE be paying us annual royalties of @$8 million per year by 2026/27. Eliminating that cost alone is worth multiples of our current market cap to them.

[bmcollins] 07/9/2023 14:27

@40 Fathoms
A great spot and wouldn't it fit in nicely or more to the point, hasn't it fitted in nicely already ?
Thanks for drawing this to our attention

[40 fathoms] 07/9/2023 14:10

GEHC presented this morning on day 2 of the Wells Fargo Healthcare Conference. They had this to say around potential M&A

“Analyst:
Okay, fair enough. And switching gears, Jay, on capital allocation, what are your thoughts on M&A in terms of deal size, areas of interest, financial criteria, etc.?

James Jay Saccaro, Vice President and Chief Financial Officer: Sure.
I think M&A represents a very interesting opportunity for us. We did a deal this year called Caption Health, and really what Caption Health is about is, it's about artificial intelligence technology that supports ultrasound. And what it specifically does is, it allows somebody who is a perhaps not highly trained sonographer to have guidance that allows them to put together an ultrasound. And if you are a trained sonographer, you can move through your exams more expeditiously as a result of this technology.
It's a great example of a technology that directly relates to a product area that we have and allows us to more effectively deliver our offering. And so that's the kind of deal that we love to see. We are the logical owner of that asset. We can drive a differential value based on the other products that we provide.
A couple years ago, we did a deal called BK Medical, which is similar. It's about ultrasound therapy in terms of supporting cardiac intervention and using ultrasound to do that, another technology offering. So, as I think about M&A going going forward, clearly our wheelhouse will be in those areas where we have a strategic gap where we think it's more appropriate to close it inorganically. And there will be numerous opportunities like that. And we're spending time, Pete and I meet with the BD team every single week reviewing the pipeline, reviewing the strategies and the gaps and how these products will help close those gaps. So I'm very excited about the idea of bolt-ons. When we do, we're very focused on ROI in years three, four, five, and six. We want to have a very robust return on the investment.”

[bamboo2] 31/8/2023 22:31

Price falling on very low volume. Possible turn showing 31/8-1/9

[bamboo2] 30/8/2023 19:49

Profitability on the agenda for boss of listed ultrasound firm

By Ben Butler
29 Aug 2023

Use link for whole report.




..."As a business, we have three main focuses," he said.

"These are growing the clinical AI revenues, continuing to build the simulation business revenues and reach profitability with the current cash by the end of next year target."

The group's clinical AI products is also a big priority for Gall, with them continuing to gain traction with revenues more than doubling to £700,000 compared to £300,000 the previous year.

"We've seen positive trading for the last three years and the latest results are another one," he said. The key aspects of this are have we sold more AI related software? The answer is yes and we want revenue to be in the millions.

"Increasing our marketing in America has been very important also in delivering revenues and we've started doing that properly. We've increased our team to generate leads and increase sales.

"So we're very positive about America and the rest of the world is coming on also. We have a good team and the right product in the right marketplace to make it sell fast."

In terms of outlook for the remainder of the year, Gall said the firm is on track to meet expectations of £12.5m revenue for the full year.

"As we stand right now, providing there are no major shocks or changes, we expect to meet and are on target for £12.5m revenue," he said.

Gall said the firm is also "on track" to more than double turnover by 2025.

He added: "The target is to hit £25m turnover by the end of 2025. AI makes up a massive part of that...

[bamboo2] 29/8/2023 20:48

Symmetrical triangles break out around 75% of their length.

[bamboo2] 24/8/2023 09:56

50/100/200SMAs all rising below a rising share price for the first time since December 2021

[bamboo2] 23/8/2023 22:56

For info, if anyone wants more detail on the forecasts, Cenkos have free registration for the IUG broker note.

It is marked, "Not to be distributed anywhere. Strictly for personal use." so you have to get your own copy.

[bamboo2] 21/8/2023 16:47

Good to see the start of the Masterclass Webinar series.

Undoubtedly this also has a role in the sales process.

It occurs the day after the 2023 meeting of the American Association of Nurse Anesthesiology where IUG are currently exhibiting.

========================================================

'Ultrasound-Guided Needling with NeedleTrainer'

Wednesday, 23rd August 2023
3PM BST / 10AM ET

PURPOSE

Ultrasound-guided needling is a difficult skill to learn. Trainers face restrictive conditions with patient safety paramount over training, and little chance of self-directed practise.

In this 1-hour masterclass session, clinical applications specialist Sue Halterman will talk through the skills common to ultrasound-guided needling across multiple clinical specialties, and show you how NeedleTrainer™ can be tailored to teach ultrasound-guided needling to any medical trainee, from anesthesia to nephrology.

Learn the skills of ultrasound-guided needling common to any specialty
Discover how training can be tailored to your department
Explore tips and tricks for learning needle-probe coordination
Witness safe, non-invasive ultrasound-guided needling live, with NeedleTrainer™

[bamboo2] 21/8/2023 16:43

Nice bit of volume today, along with a rising share price.

[bamboo2] 21/8/2023 08:55

Hi 40F, thanks for the reasoning. Look forward to your new findings.

[40 fathoms] 21/8/2023 08:39

@Bamboo, Yes removed the post as it just felt a bit rampy when I re-read it. I am working on proving some of the ideas and will post something similar if and when I can find some supporting evidence.

[bamboo2] 21/8/2023 08:27

40F, sorry you had second thoughts about your post, there's nothing wrong with a little speculation. The 25 by 25 objective also looks reasonable to me.

When you look at how GEHC is developing its AI offering, eg the Edison Platform, you can see how things could take off, once IUG products become more standardised in the GE range. It would be good to see evidence of GEHC addressing their order book backlog, as this must be holding things up a bit for us.

[eeza] 18/8/2023 22:03

Interview with Gall also on Vox.

[bmcollins] 18/8/2023 18:48

@bamboo2
Interesting report
Not much space for the board to add by sounds of it, I have added but modestly.
I think we can be bullish on this stock.

[bamboo2] 18/8/2023 18:21

This afternoon I was in the market for 75k, but could only get 2 x 25k in dribs and drabs, the last order was timed out of ordinary trading hours so I cancelled it around 5pm.

During this time there was enough demand at 10.1p to sell 100k on auto-quote.

[bamboo2] 18/8/2023 14:23

bmcollins, Management currently hold around 1.07%
Approx 3.5m shares.
Using their own funds to increase holdings would be a positive for me.

Institutions are up to approx 80% now.

[bmcollins] 18/8/2023 12:18

@bamboo
Read 40 fathoms, if 77% is owned already by the top 10 shareholders and management they have plenty of skin in the game already, surely ?

[bamboo2] 18/8/2023 11:36

Wonder if we will see some director buying?

It might help give the story more conviction.